You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for Patent: 9,339,489

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,339,489 protect, and when does it expire?

Patent 9,339,489 protects SPRITAM and is included in one NDA.

This patent has twenty patent family members in nine countries.

Summary for Patent: 9,339,489

Title:	Rapid disperse dosage form containing levetiracetam
Abstract:	A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 10 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to levetiracetam.
Inventor(s):	Jacob; Jules (Yardley, PA), Coyle; Norman (Fort Washington, PA), West; Thomas G (Lawrenceville, NJ), Monkhouse; Donald C. (Radnor, PA), Surprenant; Henry L. (Phoenixville, PA), Jain; Nemichand B. (Princeton Junction, NJ)
Assignee:	Aprecia Pharmaceuticals Company (Langhorne, PA)
Application Number:	14/277,901
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Device; Dosage form;

Drugs Protected by US Patent 9,339,489

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Aprecia Pharms	SPRITAM	levetiracetam	TABLET, FOR SUSPENSION;ORAL	207958-004	Jul 31, 2015		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			METHOD OF ADMINISTERING LEVETIRACETAM	⤷ Sign Up
Aprecia Pharms	SPRITAM	levetiracetam	TABLET, FOR SUSPENSION;ORAL	207958-001	Jul 31, 2015		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			METHOD OF ADMINISTERING LEVETIRACETAM	⤷ Sign Up
Aprecia Pharms	SPRITAM	levetiracetam	TABLET, FOR SUSPENSION;ORAL	207958-002	Jul 31, 2015		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			METHOD OF ADMINISTERING LEVETIRACETAM	⤷ Sign Up
Aprecia Pharms	SPRITAM	levetiracetam	TABLET, FOR SUSPENSION;ORAL	207958-003	Jul 31, 2015		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			METHOD OF ADMINISTERING LEVETIRACETAM	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,339,489

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014228990	⤷ Sign Up
Australia	2017202752	⤷ Sign Up
Canada	2906029	⤷ Sign Up
China	105188849	⤷ Sign Up
China	109908355	⤷ Sign Up
European Patent Office	2968994	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.